Meta-Analysis of Real-World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension.

ABSTRACT: Riociguat is a drug that improves hemodynamic parameters and increases the exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH). This meta-analysis evaluated cohort studies that measured changes in parameters such as the 6-minute walk distance (6MWD), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), cardiac output (CO), and pulmonary arterial wedge pressure (PAWP). The study utilized cohort studies with a paired samples group design to measure the changes in these parameters. We searched for articles containing the keywords "Riociguat" and "Chronic thromboembolic pulmonary hypertension" in their titles in PubMed, Web of Science, Scopus, and ScienceDirect databases until May 2024. We conducted five meta-analyses to combine the

SUBMITTER: Pamukcu E 

PROVIDER: S-EPMC11831188 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature